The complex interactions among RTKs are one of the principal mechanisms of resistance to both anti-EGFR/HER1 monoclonal antibodies (cetuximab or panitumumab in CRC) and small inhibitors of the ATP binding pocket of the EGFR receptor (erlotinib and gefitinib in NSCLC). Here, EGFR is linked to colorectal carcinoma.